Fixed-Dose Isosorbide Dinitrate-Hydralazine: Race-Based Cardiovascular Medicine Benefit or Mirage?

Hypertension Prevalence of the 1984 Joint National Committee the United States, “Final Report of the Subcommittee on Definition and prevalence and the Status of Awareness, Treatment, and Control,” Hypertension 7, no. 3 (1985): 457–468.

American Heart Association, “Heart Failure,” available at <http://www.americanheart.org/presenter.jhtml?identifier=1486> (last visited May 12, 2008).

Thom T. Haase N. Rosamond W. , “Heart Disease and Stroke Statistics — 2006 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation 113, no. 6 (February 2006): e85–e151.

Centers for Disease Control and Prevention, National Vital Statistics Deaths, Percent of Total Deaths, and Death Rates for the 15 Leading Causes of Death in 10-Year Age Groups, by Race and Sex: US, 2003, available at <http://www.cdc.gov/nchs/data/dvs/lcwk2_2003.pdf> (last visited May 12, 2008).

See Thom Haase Rosamond , supra note 3.

Krumholz H. M. Parent E. M. Tu N. Vaccarino V. Wang Y. Radford M. J. Hennen J. , “Readmission After Hospitalization for Congestive Heart Failure among Medicare Beneficiaries,” Archives of Internal Medicine 157, no. 1 (1997): 99–104.

Lillie-Blanton M. Maddox T. M. Rushing O. , “Disparities in Cardiac Care: Rising to the Challenge of Healthy People 2010,” Journal of the American College of Cardiology 44, no. 3 (August 4, 2004): 503–508.

Yancy C. W. , “Heart Failure in African Americans,” American Journal of Cardiology 96, no. 7 (2005): 3–12.

See Thom Haase Rosamond , supra note 3.

See Yancy , supra note 9.

Exner D. V. Dries D. L. Domanski M. J. , “Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction,” New England Journal of Medicine 344, no. 18 (May 3, 2001): 1351–1357.

See Yancy , supra note 9.

Julius S. Alderman M. H. Beevers G. , “Cardiovascular Risk Reduction in Hypertensive Black Patients with Left Ventricular Hypertrophy: The LIFE Study,” Journal American College Cardiology 43, no. 6 (2004): 1047–1055.

Although existing data were imperfect, it suggested a tantalizing lead. See Yancy , supra note 9.

Taylor A. L. Ziesche S. Yancy C. , “Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure,” New England Journal of Medicine 351, no. 20 (2004): 2049–2057.

Tam S. W. Sbolinski M. L. Worcel M. Packer M. Cohn J. N. , “Lack of Bioequivalence between Different Formulations of Isosorbide Dinitrate and Hydralazine and the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine:

Ferdinand K. C. , “African American Heart Failure Trial: Role of Endothelial Dysfunction and Heart Failure in African Americans,” American Journal of Cardiology 99, no. 6 (2007): S3D–S6; Small K. M. Wagoner L. E. Levin A. M. , “Synergistic Polymorphisms of b1- and a2c-Adrenergic Receptors and the Risk of Congestive Heart Failure,” New England Journal of Medcine 347, no. 15 (2002): 1135–1142; McNamara D. M. Tam W. Sabolinski M. L. , “Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans with Heart Failure: Results from the A-HeFT Trial,” Journal of American College of Cardiology 48, no. 6 (2006): 1277–1282.

Id. (McNamara et al.)

See Taylor Ziesche Yancy , supra note 16.

Hunt S. Abraham W. T. Chin M. H. , “ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Circulation 112, no. 12 (September 20, 2005): e154–e235.

Carey L. A. Perou C. M. Livasy C. A. , “Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study,” JAMA 295, no. 21 (June 7, 2006): 2492–2502.

Centers for Disease Control and Prevention, “Healthy People 2010 Focus Area 3 Cancer Progress Review,” PowerPoint presentation available at <http://www.cdc.gov/nchs/ppt/hpdata2010/focusareas/fa03_charts.ppt> (last visited May 12, 2008).

Saul S. , “U.S. to Review Heart Drug Intended for One Race,” New York Times, June 13, 2005, available at <http://www.nytimes.com/2005/06/13/business/13cardio.html> (last visited May 27, 2008).